Seeking Alpha

Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher...

Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher John McCamant - who calls the firm one of the most exciting names in biotech. He highlights the company's B-cell lymphoma drug that is in phase 2 and landed a deal with a unit of Johnson & Johnson that includes a $150M upfront payment and a 50/50 profit/loss split worldwide.
Comments (2)
  • A SMARTER GREEK
    , contributor
    Comments (16) | Send Message
     
    An important side note on PCYC: The COB and CEO Mr. Bob Duggan is same guy that is resposible for the birth of ISRG and it Da Vinci technology, with his prior Company ComputermMotion. Bottom line from just a couple$$ to over $500 a share, 2 billion in sales. Good manager, smart and good guy to follow!
    .
    1 Mar 2012, 01:42 PM Reply Like
  • A SMARTER GREEK
    , contributor
    Comments (16) | Send Message
     
    great bekliever in Mr. Duggan
    1 Mar 2012, 01:43 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs